Drawing the Line: What Counts as a "Serious" Genetic Condition?

Scientists in Japan asked hundreds of adults a tough question: how serious does a genetic disease need to be before a family should be allowed to use a special medical test on embryos? The test is called PGT-M, and it checks a fertilized egg for inherited diseases before a pregnancy begins. A new study found that most Japanese adults think the current rules about this test are too strict. The research was published in the European Journal of Human Genetics.

Researchers surveyed 458 Japanese adults of child-having age to learn how they define a 'serious' genetic condition. Right now, Japan only permits PGT-M for diseases that are almost certain to be fatal in very young children. But the study found that most people have a much wider idea of what 'serious' really means. This creates a large gap between public opinion and current law.

More than half of those surveyed — about 57% — said a disease is serious if there is a 50 to 74 percent chance of getting it. About half also said a disease counts as serious if it limits a child's life only to school age or early teenage years. Nearly 44% said even a moderate disability — where someone can still live on their own but with reduced ability — is serious enough. These numbers show that the public draws the line in a very different place than the government does.

The biggest barrier to using PGT-M was not ethics — it was money. About 70% of people said the high cost was the main thing stopping them. In Japan, PGT-M is classified as experimental, so health insurance does not cover it. One cycle of testing can cost more than one million Japanese yen, which is roughly $7,000 to $9,000 in U.S. dollars.

The study also explored a Japanese concept called 'inochi no senbetsu,' which translates to 'sorting lives.' Some people worry that choosing which embryos to use is like deciding which lives are worth living. About 72% of people had heard this phrase, and 41% expressed some ethical concern about it. However, most people did not believe PGT-M was truly the same as sorting lives — they saw it more as preventing suffering.

People who felt guilt about PGT-M were actually more likely to say they would still use it. This seems like a contradiction, but researchers say it shows people can hold two ideas at once. They may feel uneasy about the concept in general but still see it as the right choice for their own family. Strict rules seemed to add guilt without actually changing people's decisions.

There was a very clear line in the survey between preventing disease and enhancing traits. Between 71% and 80% of people supported using PGT-M to prevent disease or disability. Only 6% to 10% supported using it to select for traits like intelligence or athletic ability. Similar findings have appeared in studies from Norway and the United States, showing this boundary is shared across cultures.

How serious a disease feels also depends on what support a family has access to. About 84% of people said that financial support affects whether they see a condition as 'serious.' If families know they will get help caring for a sick child, the disease may feel less overwhelming. This supports the idea that disability is shaped as much by social resources as by medical facts.

Researchers say Japan's PGT-M policy has barely changed in nearly 30 years and was built on assumptions rather than evidence. They argue that patients should be included in decisions about the rules, and that costs should be covered by insurance or government programs. About 34% of survey participants preferred insurance coverage, and another 34% preferred government subsidies. Only 23% felt families should pay the full cost themselves.

In the end, the study's authors say the public is not asking for no rules or a complete ban. People want thoughtful, case-by-case decisions that focus on preventing disease, supporting families, and respecting personal choice. A policy that listens to patients and relies on real evidence — rather than outdated ideology — can better serve families affected by serious genetic conditions. The researchers hope their findings help push Japan's policy in a new direction.